LTR PharmaASX:LTP -4.27%15 Quick Ratio is 57.40 as of Dec. 2025, which is 77% above its 10-year median of 32.49. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, LTR Pharma ranks better than 98.94% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. LTR Pharma's quick ratio for the quarter that ended in Dec. 2025 was 57.40.
LTR Pharma has a quick ratio of 57.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for LTR Pharma's Quick Ratio or its related term are showing as below:
ASX:LTP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.31 Med: 32.49 Max: 343.33
Current: 57.4
During the past 5 years, LTR Pharma's highest Quick Ratio was 343.33. The lowest was 0.31. And the median was 32.49.
ASX:LTP's Quick Ratio is ranked better than 98.94% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:LTP: 57.40
LTR Pharma (ASX:LTP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
LTR Pharma Quick Ratio Related Terms
LTR Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, LTR Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where LTR Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
LTR Pharma's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTR Pharma (ASX:LTP) has a Quick Ratio of 57.40 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on LTR Pharma and its competitors. This is 77% above median its historical median of 32.49. Over the past decade, LTR Pharma's Quick Ratio has ranged from 0.31 to 343.33. According to the industry distribution chart, LTR Pharma ranks #15 out of 1416 companies in the Biotechnology industry, placing it in the top 1.1%.
Is LTR Pharma's Quick Ratio too high?
LTR Pharma's current Quick Ratio of 57.40 is 77% above median its 10-year median of 32.49. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 343.33. The Biotechnology industry median Quick Ratio is 3.60. LTR Pharma's value of 57.40 is 1494.4% above this industry median. Based on the distribution chart, LTR Pharma ranks #15 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #15 out of 1416 companies for Quick Ratio. This places LTR Pharma in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. LTR Pharma's value of 57.40 is 1494.4% above this benchmark. Historically, LTR Pharma's own Quick Ratio has ranged from 0.31 to 343.33 over the past decade. While the company's 10-year median is 32.49 vs. the industry median of 3.60, LTR Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LTR Pharma's current Quick Ratio of 57.40 is 1494.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current Quick Ratio is 57.40, which is 77% above median its own 10-year median of 32.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Quick Ratio of 57.40. The current Quick Ratio is 57.40, which is 77% above median its 10-year median of 32.49 and 1494.4% above the Biotechnology industry median of 3.60. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Quick Ratio is 57.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 